Company News »

INVESTOR ALERT: Investigation on Behalf of AcelRx Pharmaceuticals, Inc. Shareholders Announced by Glancy Binkow & Goldberg LLP

Business Wire
Share on StockTwits
Published on

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of purchasers of the securities of AcelRx Pharmaceuticals, Inc. (“AcelRx” or the “Company”) (NASDAQ:ACRX) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by AcelRx between December 2, 2013 and September 26, 2014, concerning the Company’s operations and financial prospects.

Please contact Lesley Portnoy at (646) 539-8980, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

AcelRx is a development stage specialty pharmaceutical company, focused on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The investigation is related to the Company’s September 26, 2014, announcement that the Company’s New Drug Application (NDA) for ZalvisoTM (sufentanil sublingual tablet system) will qualify as a Class 2 resubmission with a review period of six months, and AcelRx is targeting resubmission of the NDA for first quarter 2015 or later, subject to feedback from the FDA.

The Company previously announced in a July 28, 2014, regulatory filing that it anticipated resubmitting the NDA by the end of 2014, after receiving a Complete Response Letter from the FDA requesting additional information on the Zalviso System concerning proper use of the device, optical system errors, changes to the instructions for use of the device, and submission of additional data to support the shelf life of the product.

Following the September 26, 2014, disclosure, AcelRx shares dropped nearly 20%, or $1.31 per share, on extremely heavy volume.

If you purchased AcelRx securities between December 2, 2013 and September 26, 2014, if you have information, or would like to learn more, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at (646) 539-8980, Toll Free at (888) 773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Share on StockTwits